A Phase 2, Open-label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metatstatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD).

Project: Research

StatusActive
Effective start/end date3/04/1930/04/24

Keywords

  • Medical Oncology
  • Prostrate Cancer
  • Clinical trial